中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.029 seconds)

    Hydrophobic Active Agent Compositions and Related Methods
    21.
    发明申请
    Hydrophobic Active Agent Compositions and Related Methods 审中-公开
    疏水活性剂组合物及相关方法

    公开(公告)号：US20110142945A1

    公开(公告)日：2011-06-16

    申请号：US13029989

    申请日：2011-02-17

    Applicant: Feng-Jing Chen ,  Kathryn Gutke ,  Srinivasan Venkateshwaran ,  Mahesh V. Patel

    Inventor： Feng-Jing Chen ,  Kathryn Gutke ,  Srinivasan Venkateshwaran ,  Mahesh V. Patel

    IPC: A61K9/14 ,  A61K31/5685

    CPC classification number: A61K38/13 ,  A61K9/4858 ,  A61K9/4866

    Abstract: Compositions and methods for providing hydrophobic active agents in a bioavailable form are disclosed and described. In one aspect of the invention, pharmaceutical composition containing a testosterone ester is provided. The composition includes a testosterone ester in both dissolved form and as undissolved particles and the dissolved form comprises at least 35 wt % of the testosterone ester present in the composition. The composition further includes a solubilizer and a stabilizer.

    Abstract translation: 公开和描述了以生物可利用形式提供疏水性活性剂的组合物和方法。 在本发明的一个方面，提供了含有睾酮酯的药物组合物。 组合物包括溶解形式的睾酮酯和未溶解的颗粒，溶解形式包含组合物中存在的至少35重量％的睾酮酯。 组合物还包括增溶剂和稳定剂。

    Anti-inflammatory and analgesic compositions and related methods
    24.
    发明申请
    Anti-inflammatory and analgesic compositions and related methods 审中-公开
    抗炎镇痛成分及相关方法

    公开(公告)号：US20070281927A1

    公开(公告)日：2007-12-06

    申请号：US11448597

    申请日：2006-06-06

    Applicant: Shanthakumar Tyavanagimatt ,  David Fikstad ,  Chandrashekar Giliyar ,  Mahesh Patel ,  Srinivasan Venkateshwaran

    Inventor： Shanthakumar Tyavanagimatt ,  David Fikstad ,  Chandrashekar Giliyar ,  Mahesh Patel ,  Srinivasan Venkateshwaran

    IPC: A61K31/5415

    CPC classification number: A61K31/5415 ,  A61K9/2054 ,  A61K9/4858 ,  A61K9/5084

    Abstract: Methods and compositions for delivering a meloxicam compound are disclosed and described. In one aspect, a method may include perorally administering to a subject a therapeutically effective amount of a meloxicam compound that provides a meloxicam plasma concentration within 1 hour which is at least about 40% of the maximum plasma concentration attained by the formulation. In another aspect, a composition may include a therapeutically effective amount of a meloxicam compound in a pharmaceutically acceptable carrier including at least one of an alkalizer or a solubilizer, with the meloxicam compound having a solubility in the carrier that is greater than about 1.0 mg/gm.

    Abstract translation: 公开和描述了递送美洛昔康化合物的方法和组合物。 一方面，方法可以包括向受试者口服施用治疗有效量的美洛昔康化合物，所述美洛昔康化合物在1小时内提供美洛昔康血浆浓度，其为制剂达到的最大血浆浓度的至少约40％。 另一方面，组合物可以包括药学上可接受的载体中的治疗有效量的美洛昔康化合物，其包括碱化剂或增溶剂中的至少一种，其中美洛昔康化合物在载体中的溶解度大于约1.0mg / gm。

    ORAL DOSAGE FORMS FOR OXYGEN CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMERS
    29.
    发明申请
    ORAL DOSAGE FORMS FOR OXYGEN CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMERS 有权
    含有活性剂和含OYYY聚合物的含氧化合物的口服剂型

    公开(公告)号：US20150087666A1

    公开(公告)日：2015-03-26

    申请号：US14555043

    申请日：2014-11-26

    Applicant: Chandrashekar Giliyar ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    Inventor： Chandrashekar Giliyar ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    IPC: A61K31/485 ,  A61K31/194 ,  A61K31/4402

    CPC classification number: A61K31/485 ,  A61K9/0053 ,  A61K9/2054 ,  A61K31/09 ,  A61K31/137 ,  A61K31/194 ,  A61K31/4402 ,  A61K45/06 ,  A61K2300/00

    Abstract: The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, a tri-oxy active agent, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is from about 4×10−4 moles to about 2.0×10−3 moles. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cmax for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cmax provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.

    Abstract translation: 所公开的发明涉及提供具有至少三个含氧基团的活性剂，三氧基活性剂以及第二活性成分的药物片剂。 三种含氧基活性剂的非限制性实例包括愈创甘油醚，可待因，氢可酮及其药学上可接受的盐。 在一个实施方案中，提供了每12小时一次口服给药的药物片剂。 片剂包括第一活性剂，其为三氧基活性剂，第二活性剂和释放速率控制非离子含氧基的亲水性聚合物。 片剂中亲水性聚合物的总氧基含量为约4×10 -4摩尔至约2.0×10 -3摩尔。 片剂是基质片剂，并且在禁食条件下向受试者单剂量施用一种或多种片剂提供了每种第一活性剂和第二活性剂的平均C max，其为相应平均值的70％至135％ Cmax通过在禁食状态下每隔4〜6小时在12小时时间内向受试者施用立即释放的口服剂型，其中在每个活性剂的12小时时间段内施用的累积剂量相当于 药物片剂中的每种活性剂。

Patent Agency Ranking